---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-012182"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:23:27.164309+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene reports positive Phase 2 VISIONARY-MS LTE results for CNM-Au8 at AAN; shows repair and remyelination evidence

## Summary
- CNM-Au8 treatment up to 3 years showed significant vision improvement (low contrast letter acuity, p<0.001) and cognition (SDMT, p<0.001) vs original baseline.
- Physiologic markers of remyelination improved: mfVEP amplitude p<0.01, latency p=0.06.
- MRI measures of T2 lesion myelin water fraction and magnetization transfer ratio improved (p<0.05 and p=0.06), indicating structural repair.
- No significant safety findings; CNM-Au8 well-tolerated over long-term.

## SEC filing metadata
- accession: 0001437749-24-012182
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924012182/0001437749-24-012182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924012182/clnn20240415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-012182
- JSON: https://secwatch.observer/filing/0001437749-24-012182.json
- Plain text: https://secwatch.observer/filing/0001437749-24-012182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.